Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-01-02 Governance Information
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司章程（2024年1月修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (公司章程) of 奥锐特药业股份有限公司 (Aurisco Pharmaceutical Co., Ltd). It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share transfer, and other corporate governance matters. It is a comprehensive legal and governance document that sets out the internal rules and regulations of the company. There is no indication that this is an announcement, a financial report, or a meeting transcript. The content aligns with governance information about the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2024-01-02 Chinese
奥锐特药业股份有限公司第三届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 奥锐特药业股份有限公司. It details the meeting date, attendance, and voting results on various proposals, including amendments to the company charter, governance policies, guarantees, financing applications, and scheduling of a shareholders meeting. The document references other announcements published elsewhere for detailed content. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is a formal disclosure of board decisions and management actions. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2423 characters, which is consistent with a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2024-01-02 Chinese
奥锐特药业股份有限公司关于修订《公司章程》及制定、修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association and the formulation and revision of certain governance systems. It details changes to governance rules, committee responsibilities, and nomination procedures. The document is a formal announcement by the company's board about governance-related changes and does not contain financial statements or detailed financial data. It is not a full annual or interim report, nor is it a proxy solicitation or voting results announcement. The content fits best under Governance Information (CGR) as it focuses on internal rules, board structure, and governance practices.
2024-01-02 Chinese
关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件的第二轮审核问询函回复报告(修订稿)
Regulatory Filings Classification · 95% confidence The document is a detailed response report to a second round of review inquiries from the Shanghai Stock Exchange regarding the company's application for issuing convertible corporate bonds to unspecified investors. It includes extensive technical, market, and project implementation details about the company's fundraising projects, specifically the construction of production lines for pharmaceutical products. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory filing related to the company's capital raising activities and the associated review process by the stock exchange. The document length is substantial (over 12,000 characters) and contains detailed responses to regulatory inquiries, which aligns with the nature of a Regulatory Filing (RNS).
2023-12-05 Chinese
奥锐特药业股份有限公司关于向不特定对象发行可转换公司债券的第二轮审核问询函回复等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding updates to its application files for issuing convertible bonds to unspecified investors. It references regulatory review and responses to inquiry letters from the Shanghai Stock Exchange and the China Securities Regulatory Commission. The document is short (895 characters) and primarily informs about the status and updates of regulatory filings related to financing activities. It does not contain actual financial statements or detailed financial data but rather updates on the review process and regulatory compliance. Therefore, it is best classified as a Capital/Financing Update (CAP).
2023-12-05 Chinese
奥锐特药业股份有限公司关于召开2023年第三季度报告业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会). It mentions the date, time, location, and participation method for the meeting, which is a typical investor conference call or earnings call event. It references the previously published 2023 third quarter report but does not contain any financial data or analysis itself. The document is short (1441 characters) and serves as a notice for the upcoming earnings call rather than the call transcript or the financial report itself. Therefore, the document is best classified as a Call Transcript (CT) announcement or related to earnings call. However, since it is only an announcement of the meeting and not the transcript, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call meeting. Given the options, the closest and most appropriate classification is Regulatory Filings (RNS).
2023-11-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.